Millipore Sigma Vibrant Logo

341607 FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem

The FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 controls the biological activity of FGF/VEGF Receptor Tyrosine Kinase. Primarily used for Phosphorylation & Dephosphorylation applications.

MSDS (material safety data sheet) o SDS, certificato d’analisi (CoA) e certificato di qualità (CoQ), dossier, brochure e altri documenti disponibili.

Sinonimi: 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX

View Products on Sigmaaldrich.com
341607
Visualizza prezzi e disponibilità

Panoramica

Replacement Information

Tabella delle specifiche principali

CAS #Empirical Formula
219580-11-7C₂₈H₄₁N₇O₃

Prezzi e disponibilità

Numero di catalogo DisponibilitàConfezionamento Qtà/conf Prezzo Quantità
341607-5MG
Verifica della disponibilità in corso...
—
Disponibilità limitata Disponibilità limitata
A magazzino 
Fuori produzione
Disponibili quantità limitate
La disponibilità deve essere confermata
    Prodotti rimanenti: riceverà un nostro avviso
      Prodotti rimanenti: riceverà un nostro avviso
      Will advise
      Contatti il Servizio Clienti
      Contact Customer Service

      		 Fiala di plastica 5 mg
      Ricerca del prezzo in corso...
      Non è stato possibile trovare il prezzo
      La quantità minima deve essere un multiplo di
      Maximum Quantity is
      Al termine dell'ordine Maggiori informazioni
      Lei ha salvato ()
       
      —
      Richiedi il prezzo
      		 —
      Description
      OverviewA cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
      Catalogue Number341607
      Brand Family Calbiochem®
      Synonyms1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX
      References
      ReferencesKoziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.
      Product Information
      CAS number219580-11-7
      FormYellow solid
      Hill FormulaC₂₈H₄₁N₇O₃
      Chemical formulaC₂₈H₄₁N₇O₃
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Irritant
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Numero di catalogo GTIN
      341607-5MG 04055977195200

      Documentation

      FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem MSDS

      Titolo

      Scheda di sicurezza (MSDS) 

      FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem Certificati d'Analisi

      TitoloNumero di lotto
      341607

      Riferimenti bibliografici

      Panoramica delle referenze
      Koziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.
      Scheda tecnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-May-2011 RFH
      Synonyms1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX
      DescriptionA cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number219580-11-7
      Chemical formulaC₂₈H₄₁N₇O₃
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Irritant
      ReferencesKoziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.